Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 sept. 2023 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the...
Elucida Oncology Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
11 sept. 2023 10h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today an...
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
07 sept. 2023 16h01 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
06 sept. 2023 07h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today revealed new nationwide survey results indicating...
Genelux Corporation Announces New Chief Financial Officer
28 août 2023 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the...
Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer
24 août 2023 11h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...
Ovarian Cancer Market to Grow Rapidly at a CAGR of 16% by 2030 | DataM Intelligence
04 août 2023 11h00 HE
|
DataM Intelligence
New York, Aug. 04, 2023 (GLOBE NEWSWIRE) -- The Global Ovarian Cancer Market is estimated to grow at a CAGR of 16% during the forecast period (2023-2030). Ovarian cancer is a significant public...
IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023
03 août 2023 08h30 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
Gemcitabine HCL Market to Achieve CAGR of 7.4%, Exceeding US$ 1.3 Bn by 2031
26 juil. 2023 09h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, July 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The gemcitabine HCL market was valued at US$ 635.1 Mn in 2021 and is projected to exceed...
Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial
20 juil. 2023 11h45 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that the...